CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Xenon Reports Positive Phase 1 Results for Pain Drugs XEN1701 and XEN1120

By Public Technologies
  • Xenon Pharmaceuticals plans Phase 2 acute pain studies of XEN1701 and XEN1120 in the first half of 2027 following positive Phase 1 results.
  • XEN1701 achieved modeled NaV1.7 receptor occupancy above 75% in peripheral and central nervous systems, without consistent autonomic cardiovascular effects.
  • XEN1120 exceeded predicted effective exposures from animal models; modeling supported sustained target concentrations with maintenance dosing.
  • Both drugs were generally well tolerated, with no treatment-related, dose-limiting adverse events or adverse events leading to discontinuation.
  • A compound comparable to XEN1701 reduced evoked pain by approximately 85%-100% at the two highest doses in monkeys, without meaningful cardiovascular changes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290830PRIMZONEFULLFEED9855934) on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.